Investigating how specific protein interactions affect blood cancer development
Official title: Divergent Functions of ERK Substrate Binding Domains in Pathogenesis of Myeloproliferative Neoplasms
Funded at Research Inst of Fox Chase Can Ctr · NIH-10883645 · Data updated 2026-11-12
This study is looking at a specific pathway in cancer to find new ways to treat myeloproliferative neoplasms (MPN) by targeting certain protein interactions, which could lead to better treatments that help manage the disease without affecting all the good functions of the proteins involved.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $671,691 |
| NIH project number | 5R01CA283396-02 |
| Project ID | NIH-10883645 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms or related blood cancers.
✕Less likely to help
Patients with cancers not driven by the Ras/MAPK pathway may not benefit from this research.
What this research studies
This research focuses on understanding the Ras/MAPK signaling pathway, which is involved in many cancers, including myeloproliferative neoplasms (MPN). The researchers aim to develop new treatment strategies that target specific protein interactions rather than the active sites of kinases, which have proven ineffective. By identifying how different substrate binding domains of the ERK2 protein influence cancer progression, they hope to create therapies that can better control disease advancement. This approach may lead to more effective treatments that preserve some kinase functions while inhibiting harmful ones.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for patients with myeloproliferative neoplasms and potentially other cancers.
How similar studies have gone: While targeting the Ras/MAPK pathway has been challenging, this novel approach of focusing on substrate interactions has not been widely tested, making it a potentially groundbreaking strategy.
Where this research is happening
-
Research Inst of Fox Chase Can Ctr
Philadelphia, United States Active
Researchers
- Principal investigator: Wiest, David L. — Research Inst of Fox Chase Can Ctr
- Study coordinator: Wiest, David L.
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.